[HTML][HTML] Use of 15-valent pneumococcal conjugate vaccine among US children: updated recommendations of the Advisory Committee on Immunization Practices …

M Kobayashi - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Use of 15-Valent Pneumococcal Conjugate Vaccine Among US Children: Updated
Recommendations of the Advisory Committee on Immunization Practices — United States …

Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study

MR Moore, R Link-Gelles, W Schaffner… - The Lancet …, 2016 - thelancet.com
Summary Background In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was
licensed and recommended in the USA for prevention of invasive pneumococcal disease in …

Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices …

Centers for Disease Control and … - MMWR. Morbidity …, 2010 - pubmed.ncbi.nlm.nih.gov
On February 24, 2010, a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13,
Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) was licensed by the Food and Drug …

Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine-United States, 2007

Centers for Disease Control and … - MMWR. Morbidity …, 2010 - pubmed.ncbi.nlm.nih.gov
Invasive pneumococcal disease (IPD), caused by Streptococcus pneumoniae
(pneumococcus), remains a leading cause of serious illness in children and adults …

[HTML][HTML] A phase II trial of safety, tolerability and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal …

HL Platt, D Greenberg, B Tapiero… - The Pediatric …, 2020 - journals.lww.com
Background: Pneumococcal disease remains a public health priority worldwide. This phase
2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and …

[HTML][HTML] Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants in the United States

S Senders, NP Klein, E Lamberth… - The Pediatric …, 2021 - journals.lww.com
Background: The development and widespread use of pneumococcal conjugate vaccines
(PCVs) substantially reduced the global burden of pneumococcal disease. Expanding the …

Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical …

J Spijkerman, RH Veenhoven, AJ Wijmenga-Monsuur… - Jama, 2013 - jamanetwork.com
Importance Immunization schedules with pneumococcal conjugate vaccine (PCV) differ
among countries regarding the number of doses, age at vaccinations, and interval between …

[HTML][HTML] Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal …

JP Nuorti, CG Whitney - 2010 - cdc.gov
SUMMARY On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein
conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer …

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers

SH Yeh, A Gurtman, DC Hurley, SL Block… - …, 2010 - publications.aap.org
BACKGROUND: 7-Valent pneumococcal conjugate vaccine (PCV7 [Prevnar, Wyeth
Pharmaceuticals Inc, Philadelphia, PA], serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) is …

The worldwide impact of the seven-valent pneumococcal conjugate vaccine

SP Fitzwater, A Chandran, M Santosham… - The Pediatric …, 2012 - journals.lww.com
Background: Pneumococcal conjugate vaccines (PCV) are emerging as one of the most
promising means to prevent pediatric disease. The 7-valent PCV (PCV-7) has been …